Prognostic factor in patient with recurrent pancreatic adenocarcinoma.
Blood transfusion
Carbohydrate antigen 19-9
Low albumin
Pancreatic adenocarcinoma
Recurrence
Journal
Langenbeck's archives of surgery
ISSN: 1435-2451
Titre abrégé: Langenbecks Arch Surg
Pays: Germany
ID NLM: 9808285
Informations de publication
Date de publication:
02 Sep 2023
02 Sep 2023
Historique:
received:
26
11
2022
accepted:
17
08
2023
medline:
5
9
2023
pubmed:
4
9
2023
entrez:
2
9
2023
Statut:
epublish
Résumé
To elucidate prognostic factors for post-recurrence survival in patients with pancreatic ductal adenocarcinoma (PDAC). Patients who underwent curative-intent surgery for PDAC between January 2014 and May 2020 were identified. Among them, patients who had postoperative recurrences and received chemotherapy were retrospectively investigated. Independent prognostic factors for survival after recurrence were investigated using multivariate analyses. Eligible patients were divided into two groups according to the presence or absence of the identified prognostic factors, and survival times after recurrence were compared. Eighty-four patients with recurrent PDAC were included. Multivariate analysis showed that red blood cell (RBC) transfusion (HR, 2.80; p = 0.0051), low albumin level (HR, 1.84; p = 0.0402), and high carbohydrate antigen 19-9 (CA19-9) level at recurrence (HR, 2.11; p = 0.0258) were significant predictors of shorter survival after recurrence. The median survival times after recurrence in the transfusion and non-transfusion groups were 5.5 vs. 18.1 months (p < 0.0001), respectively; those in the low and normal albumin groups were 10.1 vs. 18.7 months (p = 0.0049), and those in the high and normal CA19-9 groups were 11.5 vs. 22.6 months (p = 0.0023), respectively. RBC transfusion, low albumin, and high CA19-9 levels at recurrence negatively affected survival after recurrence in patients with PDAC.
Identifiants
pubmed: 37658871
doi: 10.1007/s00423-023-03073-2
pii: 10.1007/s00423-023-03073-2
doi:
Substances chimiques
CA-19-9 Antigen
0
Albumins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
347Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7–30
pubmed: 31912902
doi: 10.3322/caac.21590
Uesaka K, Boku N, Fukutomi A et al (2016) Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388:248–257
pubmed: 27265347
doi: 10.1016/S0140-6736(16)30583-9
Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–277
pubmed: 17227978
doi: 10.1001/jama.297.3.267
Schorn S, Demir IE, Samm N, Scheufele F, Calavrezos L, Sargut M et al (2018) Meta-analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma. BJS Open 2:52–61
pubmed: 29951629
pmcid: 5989995
doi: 10.1002/bjs5.46
Seelen LWF, Floortje van Oosten A, Brada LJH, Groot VP, Daamen LA, Walma MS et al (2023) Early recurrence after resection of locally advanced pancreatic cancer following induction therapy: an international multicenter study. Ann Surg 278:118–126
pubmed: 35950757
doi: 10.1097/SLA.0000000000005666
Daamen LA, Dorland G, Brada LJH, Groot VP, van Oosten AF, Besselink MG et al (2022) Preoperative predictors for early and very early disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma. HPB (Oxford) 24:535–546
pubmed: 34642090
doi: 10.1016/j.hpb.2021.09.004
Burris HA 3rd, Moore MJ, Andersen J et al (1977) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413
doi: 10.1200/JCO.1997.15.6.2403
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 12(364):1817–1825
doi: 10.1056/NEJMoa1011923
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 31(369):1691–1703
doi: 10.1056/NEJMoa1304369
Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL et al (2018) FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 379:2395–2406
pubmed: 30575490
doi: 10.1056/NEJMoa1809775
Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC et al (2022) Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial. JAMA Oncol 8:1571–1578
pubmed: 36048453
pmcid: 9437831
doi: 10.1001/jamaoncol.2022.3829
Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G et al (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387:545–557
pubmed: 26615328
doi: 10.1016/S0140-6736(15)00986-1
Daamen LA, Groot VP, Besselink MG, Bosscha K, Busch OR, Cirkel GA et al (2022) Detection, treatment, and survival of pancreatic cancer recurrence in the Netherlands: a nationwide analysis. Ann Surg 275:769–775
pubmed: 32773631
doi: 10.1097/SLA.0000000000004093
Ilmer M, Schiergens TS, Renz BW, Schneider C, Sargut M, Waligora R et al (2019) Oligometastatic pulmonary metastasis in pancreatic cancer patients: safety and outcome of resection. Surg Oncol 31:16–21
pubmed: 31473583
doi: 10.1016/j.suronc.2019.08.010
Lovecek M, Skalicky P, Chudacek J, Szkorupa M, Svebisova H, Lemstrova R et al (2017) Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: retrospective study and review of the literature. World J Gastroenterol 23:6420–6428
pubmed: 29085191
pmcid: 5643267
doi: 10.3748/wjg.v23.i35.6420
Arnaoutakis GJ, Rangachari D, Laheru DA, Iacobuzio-Donahue CA, Hruban RH, Herman JM et al (2011) Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival. J Gastrointest Surg 15:1611–1617
pubmed: 21725701
pmcid: 3160502
doi: 10.1007/s11605-011-1605-8
Homma Y, Endo I, Matsuyama R, Sho M, Mizuno S, Seyama Y et al (2022) Outcomes of lung metastasis from pancreatic cancer: a nationwide multicenter analysis. J Hepatobiliary Pancreat Sci 29:552–561
pubmed: 35179827
doi: 10.1002/jhbp.1127
Murakami Y, Uemura K, Hayashidani Y, Sudo T, Hashimoto Y, Nakagawa N et al (2008) No mortality after 150 consecutive pancreatoduodenctomies with duct-to-mucosa pancreaticogastrostomy. J Surg Oncol 97:205–209
pubmed: 18050288
doi: 10.1002/jso.20903
Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N et al (2012) Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma. J Surg Oncol 106:174–180
pubmed: 22331838
doi: 10.1002/jso.23068
Kondo N, Uemura K, Sumiyoshi T, Okada K, Seo S, Otsuka H et al (2022) Prognosis following an extended duration of adjuvant gemcitabine plus S-1 chemotherapy in patients with pancreatic ductal adenocarcinoma: analysis using inverse probability of treatment weighting. J Hepatobiliary Pancreat Sci 29:911–921
pubmed: 35435318
doi: 10.1002/jhbp.1151
Okusaka T, Ikeda M, Fukutomi A, Ioka T, Furuse J, Ohkawa S et al (2014) Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Cancer Sci 105:1321–1326
pubmed: 25117729
pmcid: 4462360
doi: 10.1111/cas.12501
Shibata Y, Uemura K, Sumiyoshi T, Okada K, Otsuka H, Serikawa et al (2023) Surgical resection for liver recurrence after curative resection of pancreatic ductal adenocarcinoma. Langenbecks Arch Surg 408:280
pubmed: 37458812
doi: 10.1007/s00423-023-03009-w
Groot VP, Gemenetzis G, Blair AB, Rivero-Soto RJ, Yu J, Javed AA et al (2019) Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg 269:1154–1162
pubmed: 31082915
doi: 10.1097/SLA.0000000000002734
Kondo N, Murakami Y, Uemura K, Hayashidani Y, Sudo T, Hashimoto Y et al (2010) Prognostic impact of perioperative serum CA 19–9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 17:2321–2329
pubmed: 20336387
doi: 10.1245/s10434-010-1033-0
Kondo N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Sasaki H et al (2014) Elevated perioperative serum CA 19–9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma. J Surg Oncol 110:422–429
pubmed: 24889968
doi: 10.1002/jso.23666
Otsuka H, Uemura K, Kondo N, Sumiyoshi T, Nakagawa N, Okada K et al (2020) Clinical characteristics of initial recurrence in lung after surgical resection for pancreatic ductal adenocarcinoma. Pancreatology 20:1472–1478
pubmed: 32900632
doi: 10.1016/j.pan.2020.08.019
Blomstrand H, Green H, Fredrikson M, Gränsmark E, Björnsson B, Elander NO (2020) Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel. BMC Cancer 20:950
pubmed: 33008332
pmcid: 7530950
doi: 10.1186/s12885-020-07426-8
Kanda T, Wakiya T, Ishido K, Kimura N, Nagase H, Kubota S et al (2021) Intraoperative allogeneic red blood cell transfusion negatively influences prognosis after radical surgery for pancreatic cancer: a propensity score matching analysis. Pancreas 50:1314–1325
pubmed: 34860818
doi: 10.1097/MPA.0000000000001913
van Oosten AF, Daamen LA, Groot VP, Biesma NC, Habib JR, van Goor IWJM et al (2023) Predicting post-recurrence survival for patients with pancreatic cancer recurrence after primary resection: a bi-institutional validated risk classification. Eur J Surg Oncol 29:S0748-7983(23)00464-X
Kondo N, Uemura K, Sudo T, Hashimoto Y, Sumiyoshi T, Okada K et al (2021) A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact. Eur J Cancer 159:215–223
pubmed: 34781169
doi: 10.1016/j.ejca.2021.10.012
Golan T, Hammel P, Reni M et al (2019) Maintenance olaparib for germline BRCA—mutated metastatic pancreatic cancer. N Engl J Med 381:317–327
pubmed: 31157963
pmcid: 6810605
doi: 10.1056/NEJMoa1903387
Opelz G, Sengar DP, Mickey MR et al (1973) Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 5:253–259
pubmed: 4572098
Opelz G, Terasaki PI (1978) Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl JMed 299:799–803
doi: 10.1056/NEJM197810122991503
Remy KE, Hall MW, Cholette J, Juffermans NP, Nicol K, Doctor A et al (2018) Mechanisms of red blood cell transfusion-related immunomodulation. Transfusion 58:804–805
pubmed: 29383722
pmcid: 6592041
doi: 10.1111/trf.14488
Acheson AG, Brookes MJ, Spahn DR (2012) Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and metaanalysis. Ann Surg 256:235–244
pubmed: 22791100
doi: 10.1097/SLA.0b013e31825b35d5
Amato A, Pescatori M (2006) Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 1:CD005033
Sun C, Wang Y, Yao HS, Hu ZQ (2015) Allogeneic blood transfusion and the prognosis of gastric cancer patients: systematic review and meta-analysis. Int J Surg 13:102–110
pubmed: 25486261
doi: 10.1016/j.ijsu.2014.11.044
Dusch N, Weiss C, Strobel P, Kienle P, Post S, Niedergethmann M (2014) Factors predicting long-term survival following pancreatic resection for ductal adenocarcinoma of the pancreas: 40 years of experience. J Gastrointest Surg 18:674–681
pubmed: 24241965
doi: 10.1007/s11605-013-2408-x
Lewis R, Drebin JA, Callery MP, Fraker D, Kent TS, Gates J et al (2013) A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma. HPB (Oxford) 15:49–60
pubmed: 23216779
doi: 10.1111/j.1477-2574.2012.00571.x
Sutton JM, Kooby DA, Wilson GC, Squires MH III, Hanseman DJ, Maithel SK et al (2014) Perioperative blood transfusion is associated with decreased survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma: a multi-institutional study. J Gastrointest Surg 18:1575–1587
pubmed: 24944151
doi: 10.1007/s11605-014-2567-4
Kneuertz PJ, Patel SH, Chu CK et al (2011) Effects of perioperative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarcinoma. Ann Surg Oncol 18:1327–1334
pubmed: 21369744
doi: 10.1245/s10434-010-1476-3
Mavros MN, Xu L, Maqsood H et al (2015) Perioperative blood transfusion and the prognosis of pancreatic cancer surgery: systematic review and metaanalysis. Ann Surg Oncol 22:4382–4391
pubmed: 26293837
doi: 10.1245/s10434-015-4823-6
Sutton JM, Kooby DA, Wilson GC et al (2014) Perioperative blood transfusion is associated with decreased survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma: a multi-institutional study. J Gastrointest Surg 18:1575–1587
pubmed: 24944151
doi: 10.1007/s11605-014-2567-4
Abe T, Amano H, Hanada K et al (2017) Perioperative red blood cell transfusion is associated with poor long-term survival in pancreatic adenocarcinoma. Anticancer Res 37:5863–5870
pubmed: 28982913
Yamashita YI, Hayashi H, Imai K et al (2019) Perioperative allogeneic blood transfusion does not influence patient survival after hepatectomy for hepatocellular carcinoma: a propensity score matching analysis. World J Surg 43:2894–2901
pubmed: 31312946
doi: 10.1007/s00268-019-05085-w
Xiao H, Liu W, Quan H et al (2018) Peri-operative blood transfusion does not influence overall and disease-free survival after radical gastrectomy for stage II/III gastric cancer: a propensity score matching analysis. J Gastrointest Surg 22:1489–1500
pubmed: 29777453
pmcid: 6132396
doi: 10.1007/s11605-018-3808-8
Vetterlein MW, Gild P, Kluth LA et al (2018) Peri-operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer: a propensity score-weighted European multicentre study. BJU Int 121:101–110
pubmed: 28905486
doi: 10.1111/bju.14012
Ecker BL, Simmons KD, Zaheer S et al (2016) Blood transfusion in major abdominal surgery for malignant tumors: a trend analysis using the National Surgical Quality Improvement Program. JAMA Surg 151:518–525
pubmed: 26763765
doi: 10.1001/jamasurg.2015.5094
Nakanishi K, Kanda M, Kodera Y (2019) Long-lasting discussion: adverse effects of intraoperative blood loss and allogeneic transfusion on prognosis of patients with gastric cancer. World J Gastroenterol 25:2743–2751
pubmed: 31235997
pmcid: 6580348
doi: 10.3748/wjg.v25.i22.2743
Kondo N, Murakami Y, Uemura K, Nakagawa N, Takahashi S, Ohge H et al (2017) Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma. Pancreatology 17:95–102
pubmed: 27746094
doi: 10.1016/j.pan.2016.10.004
Moriyama J, Oshima Y, Nanami T, Suzuki T, Yajima S, Shiratori F et al (2021) Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer. Surg Today 51:1638–1648
pubmed: 33682011
doi: 10.1007/s00595-021-02248-y
van Wijk L, van der Snee L, Buis CI, Hentzen JEKR, Haveman ME, Klaase JM (2021) A prospective cohort study evaluating screening and assessment of six modifiable risk factors in HPB cancer patients and compliance to recommended prehabilitation interventions. Perioper Med (Lond) 10:5
pubmed: 33593437
doi: 10.1186/s13741-020-00175-z